MAIA 8-K: EPO Patent Decision Covers THIO Use Alone or Before CPIs

Rhea-AI Filing Summary

MAIA Biotechnology reported that the European Patent Office has decided to grant a patent that broadly covers a portfolio of ateganosine-based analogues directed to telomere-targeting anticancer therapy. The patent also covers methods of using ateganosine (THIO) either alone or prior to administration of checkpoint inhibitors (CPIs). The filing attaches a press release as Exhibit 99.1 which is incorporated by reference.

The filing contains the Companys standard forward-looking statements cautioning that future results are subject to risks and uncertainties, including the initiation, timing, cost, progress and results of preclinical and clinical studies, regulatory filings and approvals, manufacturing and commercialization, market acceptance, and intellectual property protection. No financial results or transaction terms are disclosed in this report.

Positive

• European Patent Office decision to grant a patent covering a portfolio of ateganosine-based analogues is disclosed
• Patent explicitly covers methods of using ateganosine (THIO) either alone or prior to administration of checkpoint inhibitors (CPIs)
• Press release is attached as Exhibit 99.1, providing a formal corporate disclosure of the event

Negative

• None.

Insights

Securities Analyst

TL;DR: EPO patent grant is a clear intellectual property milestone; the 8-K contains no financial details.

The European Patent Office decision to grant a patent covering ateganosine-based analogues and related methods is a material operational update about MAIAs intellectual property estate. The disclosure confirms formal IP protection in the EPO for the THIO program and explicitly includes methods of using THIO alone or before checkpoint inhibitors, which may affect clinical development strategies. Investors should note the filing does not provide scope of claims, jurisdictions beyond the EPO, or financial impact.

Intellectual Property Specialist

TL;DR: Grant of a patent that "broadly covers" ateganosine analogues and usage methods is an important patent event; claim details are not provided in the 8-K.

The 8-K states the EPO has decided to grant a patent covering a portfolio of ateganosine-based analogues and methods of using ateganosine (THIO), including use prior to checkpoint inhibitors. This is an explicit IP update confirming prosecution success at the EPO level. The report does not include patent claim language, effective scope, or prosecution history, so the exact protective breadth cannot be assessed from this filing alone. The press release is attached as Exhibit 99.1 for additional detail.

false 0001878313 0001878313 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41455		83-1495913
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

444 West Lake Street, Suite 1700
Chicago, IL		60606
(Address of principal executive offices)		(Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MAIA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 13, 2025, MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing the European Patent Office decision to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward-looking Statements

The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated August 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2025

	MAIA BIOTECHNOLOGY, INC.
	By:	/s/ Vlad Vitoc
	Name:	Vlad Vitoc
	Title:	Chief Executive Officer

3

FAQ

What did MAIA (MAIA) report in this 8-K?

The company reported that the European Patent Office decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before checkpoint inhibitors.

Is there a press release attached to the filing?

Yes. The filing states a press release is attached as Exhibit 99.1 and is incorporated by reference.

Does the 8-K include financial results or transaction terms?

No. The report provides an intellectual property update and standard forward-looking statements but does not disclose financial results, transaction terms, or quantitative financial data.

What forward-looking risks does the filing mention?

The filing lists risks including initiation, timing, cost, progress and results of preclinical and clinical studies, regulatory filings and approvals, manufacturing and commercialization, market acceptance, and maintaining intellectual property protection.

Who signed the 8-K on behalf of MAIA?

The filing is signed on behalf of the registrant by Vlad Vitoc, Chief Executive Officer.